Research Grade Briakinumab ( 布雷奴单抗 )
- 发布日期： 2020-10-28
- 更新日期： 2025-10-28
产品详请
| 产地 |
中国
|
| 品牌 |
Chemstan
|
| 货号 |
CSD00090
|
| 保存条件 |
store at -80℃
|
| 用途 |
仅用于科研用途
|
| 应用范围 |
|
| 抗原来源 |
CHO cells
|
| CAS编号 |
339308-60-0
|
| 保质期 |
一年
|
| 抗体名 |
Briakinumab ( 布雷奴单抗 )
|
| 是否单克隆 |
|
| 克隆性 |
|
| 靶点 |
IL12B[Homo sapiens]
|
| 适应物种 |
|
| 形态 |
|
| 宿主 |
|
| 标记物 |
|
| 包装规格 |
1mg/ml
|
| 纯度 |
%
|
| 亚型 |
|
| 标识物 |
|
| 浓度 |
95%
|
| 免疫原 |
|
| 是否进口 |
否
|
货号（Catalog No.）
CSD00090
通用名INN
Briakinumab
纯度(Purity)
>95%
浓度( Concentration)
1mg/ml
Formulation
PBS buffer pH7.5
Source
CHO cells
内毒素(Endotoxin level)
Please contact with the lab for this information.
生物活性
产品描述(Description)
Briakinumab is a human anti-IL-12 monoclonal antibody being developed for the treatment of a number of T-cell driven autoimmune diseases. It targets and neutralize interleukin-12 and interleukin-23, two proteins associated with inflammation, such as pro-inflammatory interleukins or tumor necrosis factor- alpha. Briakinumab represents a novel approach to treating psoriasis, Multiple Sclerosis, Crohn’s Disease and other autoimmune and inflammatory disorders. As of 2011 drug development for psoriasis has been discontinued in the U.S. and Europe.Briakinumab targets and neutralizes interleukin-12 and interleukin-23.
别名(Alternative names)
ABT-874
靶点;物种(Specificity target name;species)
IL12B[Homo sapiens]
种类(Species)
Homo sapiens
受体鉴定(Receptor identification)
IgG1-lambda
化学信息
分子量(MV)
146500.00 Da
CAS
339308-60-0
存储条件(Storage)
store at -80°C
Note
For research use only. Not suitable for clinical or therapeutic use.
